SELLAS Life Sciences Group (SLS) Projected to Post Earnings on Thursday

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) is projected to release its Q4 2024 earnings data before the market opens on Thursday, March 20th. Analysts expect SELLAS Life Sciences Group to post earnings of ($0.11) per share for the quarter.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. During the same period last year, the business earned ($1.34) EPS. On average, analysts expect SELLAS Life Sciences Group to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

SELLAS Life Sciences Group Stock Down 0.8 %

SELLAS Life Sciences Group stock traded down $0.01 during mid-day trading on Friday, hitting $1.20. 571,640 shares of the company were exchanged, compared to its average volume of 1,408,425. The business has a fifty day moving average of $1.21 and a 200 day moving average of $1.17. SELLAS Life Sciences Group has a 1-year low of $0.77 and a 1-year high of $1.84. The company has a market capitalization of $84.46 million, a PE ratio of -1.74 and a beta of 2.43.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.